Evidence map›Paper›PMID 40906651›Full record

ArticlePLOS digital health2025

Development and evaluation of a lightweight large language model chatbot for medication enquiry.

Kabilan Elangovan, Jasmine Chiat Ling Ong, Liyuan Jin, Benjamin Jun Jie Seng, Yu Heng Kwan, Lit Soo Ng, Ryan Jian Zhong, Justina Koi Li Ma, Yu He Ke, Nan Liu and 2 more

Abstract read
In one paragraph

Article in PLOS digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kabilan ElangovanSingapore Health Services, Artificial Intelligence Office, Singapore.ORCID https://orcid.org/0000-0002-7711-7368
Jasmine Chiat Ling OngDivision of Pharmacy, Singapore General Hospital, Singapore.ORCID https://orcid.org/0000-0001-6916-5960
Liyuan JinSingapore Health Services, Artificial Intelligence Office, Singapore.
Benjamin Jun Jie SengMOHH Holdings (Singapore) Private Limited, Singapore.
Yu Heng KwanDepartment of Rheumatology and Immunology, Singapore General Hospital, Singapore.
Lit Soo NgSpecialty Nursing, Nursing Division, Singapore General Hospital, Singapore.
Ryan Jian ZhongDivision of Pharmacy, Singapore General Hospital, Singapore.ORCID https://orcid.org/0009-0002-6446-0543
Justina Koi Li MaDivision of Pharmacy, Singapore General Hospital, Singapore.
Yu He KeDepartment of Anesthesiology, Singapore General Hospital, Singapore.
Nan LiuDuke-NUS AI + Medical Sciences Initiative, Duke-NUS Medical School, Singapore.
Kathleen M GiacominiDepartment of Pharmacy, University of California San Francisco, San Francisco, California, United States of America.
Daniel Shu Wei TingSingapore Health Services, Artificial Intelligence Office, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Large Language Models (LLMs) show promise in augmenting digital health applications. However, development and scaling of large models face computational constraints, data security concerns and limitations of internet accessibility in some regions. We developed and tested Med-Pal, a medical domain-specific LLM-chatbot fine-tuned with a fine-grained, expert curated medication-enquiry dataset consisting of 1,100 question and answer pairs. We trained and validated five light-weight, open-source LLMs of smaller parameter size (7 billion or less) on a validation dataset of 231 medication-related enquiries. We introduce SCORE, an LLM-specific evaluation criteria for clinical adjudication of LLM responses, performed by a multidisciplinary expert team. The best performing lighted-weight LLM was chosen as Med-Pal for further engineering with guard-railing against adversarial prompts. Med-Pal outperformed Biomistral and Meerkat, achieving 71.9% high-quality responses in a separate testing dataset. Med-Pal's light-weight architecture, clinical alignment and safety guardrails enable implementation under varied settings, including those with limited digital infrastructure.

Identifiers

PMID40906651
PMCPMC12410746

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.